Donor liver-derived FGF21 protects against tacrolimus-induced post-transplant diabetes mellitus through regulation of the CerS4/C18:0 ceramide lipotoxicity axis
Authors
Affiliations
Abstract
Post-transplant diabetes mellitus (PTDM) is a frequent metabolic complication after liver transplantation, and tacrolimus (FK506) is a major contributor. Beyond pancreatic β-cell toxicity, donor-liver-derived insulin resistance, particularly in steatotic grafts, plays a critical role. Fibroblast growth factor 21 (FGF21) improves glucose metabolism and insulin sensitivity, whereas ceramide synthase 4 (CerS4)-mediated C18:0 ceramide accumulation promotes hepatic lipotoxicity and insulin resistance. This study investigated the roles of donor-liver-derived FGF21 and the CerS4/C18:0 ceramide axis in FK506-induced glucose dysregulation after liver transplantation, and evaluated a long-acting FGF21-Fc fusion protein as a potential therapeutic strategy for PTDM. A clinical liver transplantation (LT) cohort, including steatotic-donor cases, was analyzed to assess associations among donor-liver FGF21/CerS4 expression, serum FGF21/C18:0 ceramide levels, and post-transplant glucose metabolism. Continuous FK506-exposure mouse models were established using wild-type, Fgf21-deficient, and hepatocyte-specific Fgf21 knockdown/overexpression mice under normal or steatotic conditions. Multi-omics analyses, including transcriptomics and lipidomics with WGCNA, were used to identify key lipotoxic pathways. Functional validation was performed using CerS4 overexpression and exogenous C18:0 ceramide supplementation. A long-acting FGF21-Fc fusion protein was further evaluated in mouse and rat LT models. Clinically, donor-liver and serum FGF21 levels were negatively associated with fasting blood glucose, fasting insulin, and HOMA-IR, and were significantly reduced in PTDM recipients. FK506 exposure induced glucose intolerance, insulin resistance, hepatic steatosis, and glycogen depletion in mice. These abnormalities were aggravated by Fgf21 deficiency or hepatocyte-specific knockdown, but alleviated by recombinant FGF21 or hepatocyte-specific overexpression. Multi-omics analyses identified the CerS4/C18:0 ceramide axis as the dominant FK506-induced lipotoxic pathway, which was suppressed by FGF21. Serum FGF21 inversely correlated with serum C18:0 ceramide in LT recipients, while elevated CerS4 or C18:0 ceramide was associated with worse glycemic outcomes, including in steatotic-donor recipients. Persistent CerS4 overexpression or C18:0 ceramide supplementation abolished the protective effects of FGF21. The long-acting FGF21-Fc fusion protein showed efficacy comparable to efruxifermin with reduced dosing frequency and improved 8-week survival in steatotic-graft LT rats. Donor-liver-derived FGF21 is a key protective factor against FK506-induced PTDM, and its metabolic benefit depends on negative regulation of the CerS4/C18:0 ceramide lipotoxicity axis. The long-acting FGF21-Fc fusion protein durably suppresses this axis and improves post-LT outcomes, including survival of recipients of steatotic grafts, and offering a clinically translatable strategy for PTDM prevention and treatment.

